Background Regional Drug Misuse Databases (RDMDs) are considered the main source of intelligence on problem drug takers in England. Originally intended to provide trend data on visible drug use, a recent strategic review concluded that their purpose should be to monitor treatment targets for the Government's latest 10 year strategy to tackle drug misuse. The aim of this analysis was to explore whether the General Practice Research Database (GPRD) could supplement RDMDs.
Introduction
One of the cornerstones of the UK Government's recently announced 10 year drug misuse strategy, Tackling drugs to build a better Britain, is the ability to monitor treatment targets.
1,2 A recently completed strategic review 3 of the Regional Drug Misuse Databases (RDMDs) concluded that the primary aim of`new RDMDs' should be to monitor these targets, one of which is to increase the proportion of problem drug users in contact with drugs services. This requires an assessment of the size of the drug-using population. However, as existing RDMDs accept reports from a wide range of agencies, it is dif®cult to de®ne the denominator of the reporting system and thereby adjust for under-reporting and interpret overall trends.
Before the establishment of RDMDs, trends in problematic drug use in the United Kingdom were assessed from the Home Of®ce Addicts Index (HOAI). 4 Until May 1997, medical practitioners had a statutory requirement to report patients addicted to drugs in accordance with the Misuse of Drugs Act 1971 (1973 Regulations). The legal criterion for identifying an addict is that they should have an overwhelming desire to take a drug as result of having taken it before. The regulations mention 14 drugs (13 opiates and cocaine). The number of noti®ed addicts increased every year from 20 820 in 1991 to 43 372 in 1996.
By the late 1980s there was dissatisfaction with the limitations of the HOAI and so regional drug misuse databases (RDMDs) were established in 1989. By 1992 there were RDMDs in all areas of Great Britain. 5 The main difference between the HOAI and RDMD is that the latter cover a wider range of services and a wider range of drugs. Unlike the HOAI, which recorded new and renoti®ed addicts each year, the RDMDs record only new agency contacts and reattenders after a 6 month gap, although this will be recti®ed with the implementation of the strategic review, which will introduce a system of annual follow-up of all registered clients. Because of these differences, it is dif®cult to compare the most recent ®gures from the RDMD and the HOAI. September 1997 was 27 262 compared with  43 372 for the HOAI in 1995 (new 18 281, renoti®ed 25 091 for  the HOAI in 1996) .
month period to
A particular issue of concern is the completeness of reports from general practitioners to the RDMDs. This is highlighted in the Department of Health's drug misuse statistics bulletin, 5 which notes that recent decreases in the number of individuals reported are due to changes in reporting practices rather than the number of users seeking treatment. The principal reason behind this is that before May 1997 medical practitioners had a statutory requirement to report patients addicted to drugs to the Home Of®ce Addicts Index (HOAI). 6 Doctors could use one form (with carbon copies) to provide information to both the Addicts Index and the local Regional Drug Misuse Database (RDMD). When the HOAI ceased in April 1997, doctors were told that they were no longer required to submit data to the Addicts Index. As a result, and in the absence of a statutory obligation, it appears that many doctors have stopped submitting data to the RDMD. Furthermore, although the strategic review states that general practitioners (GPs) are`core reporters' for RDMDs it does not recommend speci®c action to improve their participation.
As the Government is encouraging GPs to treat drug misusers, 7 the aim of this paper is to consider whether an existing database used by large numbers of GPs could complement current RDMDs in providing rates of presenting or recorded drug misuse in primary care. The database in question is the General Practice Research Database (GPRD), which although largely unknown in the drug misuse research community, has been extensively utilized to investigate drug safety issues. 8 Unlike the RDMD, there are fewer problems in interpreting trends because the base population is clearly speci®ed as the number of registered patients at a given point in time. Furthermore, even if GP noti®cation to the RDMDs were more complete, the type of information supplied is largely limited to new treatment episodes, without longitudinal followup. In contrast, the GPRD affords an opportunity to assess not only trends in drug misuse, but also other aspects of drug misuse such as associated psychiatric co-morbidity, coprescribing and treatment outcomes. Another strength of the GPRD is that it directly re¯ects the experience of UK doctors and patients. Since May 1999 the database has belonged to the Medicines Control Agency, which is responsible for data collection and quality monitoring. Independent studies have reported on the good quality of diagnostic and prescribing information on the database. 9 Whereas the HOAI captures information on people using hard' drugs, both the GPRD and RDMD record information on people whose drug use may be considered to be problematic, irrespective of the substance being used. For the GPRD, the data refer to cases where a GP has recorded such a diagnosis, whereas the RDMD records individuals with drug problems who are in contact with a range of medical and non-medical agencies.
The objective of this paper is to compare trends in cases of drug misuse or dependence in the West Midlands, 1993±1997, recorded on the GPRD and the RDMD. A subsidiary objective is to conduct exploratory analysis of psychiatric co-morbidity and hospital referrals relating to drug misuse or dependence. The results will determine the potential of the GPRD for monitoring drug misuse; in particular, whether it could enhance existing drug misuse surveillance mechanisms.
Methods

Database characteristics and subjects
The West Midlands GPRD data are held on a Microsoft Access relational database with tables on patient details, prescriptions and medical records (e.g. diagnoses, hospital referrals). The tables are linked by an anonymized and encrypted patient identi®er. The database contains 642 986 patient records and the time frame for the present analysis was 1993±1997. Participating GPs record every prescription and signi®cant morbidity and consultation outcomes to agreed standards. The number of practices participating (and those reporting patients diagnosed as drug misusers or dependent) was 53 (48) A comparison of the 1996 GPRD population with the mid-1996 population of England and Wales shows that the distributions are similar with regard to age and sex. 10 Socioeconomic comparisons cannot be made because the database does not contain any information on patients' socio-economic status. The 1996 population coverage for the West Midlands was 5.3 per cent compared with 3.9 per cent for the whole of England and Wales.
Birmingham Health Authority provided data from the West Midlands RDMD. The RDMD records new clients and those who reattend after a 6 month gaps; clients may also attend more than one agency. There were 91 participating agencies, although it is not possible to give a yearly breakdown. The annual time frame used in the RDMD is April±March. For the purposes of this analysis, the RDMD data were aggregated into January±December time periods and duplicate patient records within each year were eliminated.
Data
General Practice Research Database
The relevant data were extracted in a number of stages. Forty diagnostic codes relating to drug misuse or dependence and overdose were selected from the 18 695 OXMIS codes (Oxford Medical Information Systems) on the database (OXMIS codes were devised for use by GPs and are based on ICD8 codes and OPCS operation codes). 11 These codes are shown in Table 1 . All records with these codes were selected from 1993 to 1997. For patients with drug misuse or dependence diagnoses the following data were obtained: (1) psychiatric morbidity diagnoses contained in 222 OXMIS codes based on ICD headings 293±301, 306 and 781.8 (psychosis, schizophrenia, paranoid states, neurosis, personality disorders and hallucinations); (2) hospital referrals or admissions relating to drug misuse dependence; (3) all hospital referrals. OXMIS contains an extensive set of alcohol-related diagnoses, which were not considered in the current analysis.
Regional Drug Misuse Database
The total number of cases and the proportion noti®ed by GPs in the West Midlands annually from 1993 to 1997 were extracted from the RDMD.
Analysis
To compare RDMD and GPRD trends, the raw data were converted to annual noti®cation rates. For the GPRD the rates are based on the registered practice populations in each year, whereas for the RDMD the rates are based on the region's population. Estimates of the total number of patients treated for drug misuse or dependence in the West Midlands were obtained by extrapolating the number of recorded cases from the GPRD sample to the region. The multiplier for extrapolation was derived by dividing the region's population by the number of registered patients per year. The multiplier was 15 for 1993, 14.5 for 1994, 13.8 for 1995, 15.3 for 1996 and 19.0 for 1997.
Results
Between 1993 and 1997, 1308 individuals had diagnostic codes for drug misuse or dependence entered on the GPRD. The number of consultation episodes and patients for each OXMIS code are shown in Table 1 . Among practices reporting at least one drug misuse or dependence diagnosed patient, the average number of patients reported per practice was 26 and the range was 1±156 (SD 25.2). Table 2 shows the number of clients and patients reported by the RDMD and GPRD. Table 3 shows that the rate of GP referrals to the RDMD increased between 1993 and 1996 but fell markedly in 1997. In contrast, the GPRD rate for drug misuse or dependence has increased steadily since 1995. In 1997, the GPRD drug misuse or dependence rate was 40 times higher than that for GP reports to RDMD and 1.8 times the rate for the total RDMD. Figure 1 shows that the extrapolated number of patients treated by GPs in the West Midlands is consistently higher than the total number of clients reported to the RDMD. In 1997 the extrapolated number of patients in the region was 6574 compared with 3643 RDMD clients.
Co-morbidity and hospitalization
Of the 1308 drug misuse or dependence diagnosed patients, 720 (55.6 per cent) had a psychiatric morbidity diagnosis. There were a total of 1536 hospital referrals for all causes involving 535 patients (40.9 per cent). There were 195 drug-related referrals to hospital involving 128 patients (9.8 per cent). One hundred and ®ve referrals were for overdose (unspeci®ed whether intentional or accidental), 17 for suicidal overdose and the remainder for drug misuse or dependence.
Discussion
Although the RDMDs are considered the main source of intelligence on problem drug takers in England, a recent evaluation concluded that even if complete the databases would still need to be altered in order to provide reliable trend data. 12 The aim of this analysis was to explore whether the GPRD can usefully supplement current RDMDs.
Both the RDMD and GPRD record data on individuals who are recognized as being misusers or dependent. However, for the West Midlands, trends in the two databases are markedly different. Between 1993 and 1996, the rate of drug misuse or dependence reported by GPs to the RDMD increased from 3/ 100 000 to 11/100 000 but in 1997 the rate fell back to 3/ 100 000. Although the main reason for this is the reduction in the number of cases reported to the RDMD by GPs (from 602 in 1996 to 163 in 1997), there was also a fall in the number of cases reported by other sources (from 3713 in 1996 to 3480 in 1997). The latter fall may also have been due to an increase in under-reporting and perhaps a shift in treatment from specialist drug treatment centres to primary care settings. In contrast, the rate of reporting on the GPRD, having been relatively steady between 1993 and 1995, increased between 1995 and 1997 from 80/100 000 to 124/100 000. The abolition of statutory noti®cation has had no impact on the GPRD as no additional effort is required to`notify' a diagnosis of drug misuse or dependence.
This increase in the rate of recorded cases of drug misuse or dependence is concordant with other studies in the West Midlands. In the British Crime Survey, 13 the proportion of people aged 16±29 in the West Midlands who used drugs in the previous year increased from 16 to 19 per cent between 1994 and 1996. Although the West Midlands still lags behind the national rate of 24 per cent, the trend is increasing more rapidly in the region than in England as a whole.
On the basis of the GPRD data, the extrapolated number of patients being diagnosed as drug misusers or dependent in the West Midlands is considerably higher than the total number of reports to the RDMD. In 1997 the number of drug misuse diagnosed patients was 6574 compared with 3643 in the RDMD, a ratio of 1.8. Over the 5 year investigation period the ratio was 1.7. As one of the previous criticisms of the RDMDs is that they do not assess prevalence, the GPRD data may provide a more plausible estimate even though the GPRD only indicates prevalence recorded in general practice. It is, however, impossible to assess the accuracy of the estimate given that the population covered by the self-selecting practices contributing to the GPRD, although demographically similar to the population of the West Midlands as a whole may not be socio-economically similar. Although accepting that the converse could be true, we would speculate that inner city practices are under-represented and that our ®ndings underestimate prevalence. One weakness of the GPRD is that in the majority of cases, doctors do not specify the drug of misuse or dependence. Although it is possible that alcohol could be the substance of abuse, invalidating our results, we consider this most unlikely, as there are a number of OXMIS codes speci®c to alcohol and alcohol abuse. Furthermore, we discussed this point with a number of practicing GPs, all of whom volunteered that they draw a distinction between alcohol abuse and drug or substance abuse. The fact that in a minority of cases the drug is speci®ed means that doctors could be requested to include this information wherever possible. This would greatly enhance the usefulness of the GPRD in assessing treated drug misuse in general practice.
Although the main aim of this paper has been to interpret trends in drug misuse, the results on co-morbidity and hospitalization highlight the potential for monitoring drug dependence in primary care. With over half of all patients having psychiatric diagnoses, further work could focus on the time sequence between diagnoses of drug misuse or dependence and, for example, depression or anxiety. There is also considerable scope for monitoring drug overdoses. Sixty-two per cent of drug-related hospital referrals among drug-misusing patients were for overdose.
Although a previous systematic validation of specialist drug agencies to the North Thames RDMD showed that the level of under-reporting from these was between 25 and 32 per cent, 14 reporting by GPs to the RDMD was not investigated. Although this study did not directly assess under-reporting by GPs, the discrepancy between the West Midlands RDMD and GPRD indicates a high level of under-reporting to the RDMD. This is of concern, given that the strategic review of RDMDs recommends GPs as`core reporters' for providing data to the national system. Our ®ndings suggest that the GPRD would usefully supplement existing RDMDs, although possible variations between regions in GP reporting require further investigation. With regard to the proposed`new' RDMDs, there is a need for a strategy to ensure valid and comprehensive reporting from GPs.
In conclusion, this analysis has highlighted the potential for using the GPRD to augment the regional drug misuse databases. Although the results of the current study apply only to the West Midlands, the national database covers a broadly representative sample of the population in England and Wales, and therefore could provide trends in drug misuse and dependence recorded in general practices. Given that the cost of maintaining the RDMDs is approximately one million pounds per year, the GPRD could be a cost-effective way of contributing to the monitoring of drug misuse or dependence in England and Wales. Although the RDMDs yield more detailed information on types of drug misused and other indicators such as injecting, the GPRD may provide more reliable data on overall patterns and trends of drug misuse. 
